Cargando…

Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis

BACKGROUND: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GV...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarmiento Maldonado, Mauricio, Ramírez Villanueva, Pablo, Bertín Cortes-Monroy, Pablo, Jara Arias, Veronica, Soto Donoso, Katherine, Uribe Gonzalez, Pablo, Ocqueteau Tachini, Mauricio, Perez-Simón, Jose Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712115/
https://www.ncbi.nlm.nih.gov/pubmed/29214116
http://dx.doi.org/10.1186/s40164-017-0092-3
_version_ 1783283166631428096
author Sarmiento Maldonado, Mauricio
Ramírez Villanueva, Pablo
Bertín Cortes-Monroy, Pablo
Jara Arias, Veronica
Soto Donoso, Katherine
Uribe Gonzalez, Pablo
Ocqueteau Tachini, Mauricio
Perez-Simón, Jose Antonio
author_facet Sarmiento Maldonado, Mauricio
Ramírez Villanueva, Pablo
Bertín Cortes-Monroy, Pablo
Jara Arias, Veronica
Soto Donoso, Katherine
Uribe Gonzalez, Pablo
Ocqueteau Tachini, Mauricio
Perez-Simón, Jose Antonio
author_sort Sarmiento Maldonado, Mauricio
collection PubMed
description BACKGROUND: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. CASES PRESENTATION: In this report we present our experience in 8 patients with acute or chronic GVHD with refractoriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profile. CONCLUSIONS: In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment.
format Online
Article
Text
id pubmed-5712115
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57121152017-12-06 Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis Sarmiento Maldonado, Mauricio Ramírez Villanueva, Pablo Bertín Cortes-Monroy, Pablo Jara Arias, Veronica Soto Donoso, Katherine Uribe Gonzalez, Pablo Ocqueteau Tachini, Mauricio Perez-Simón, Jose Antonio Exp Hematol Oncol Case Report BACKGROUND: Ruxolitinib is a potent inhibitor of JAK1/2 with proven efficacy in myelofibrosis. In recent years, research in graft versus host disease (GVHD) has revealed the role of activation of JAK pathways in alloreactive lymphocytes. Some reports have shown significant responses in refractory GVHD patients. CASES PRESENTATION: In this report we present our experience in 8 patients with acute or chronic GVHD with refractoriness to steroids and extracorporeal photopheresis treated with ruxolitinib. Three patients had acute GVHD (1 pulmonary, 2 cutaneous, 1 multi-systemic) and 5 had chronic GVHD (3 cutaneous); 85% obtained an overall response and 50% a complete response with a tolerable toxicity profile. CONCLUSIONS: In our series, Ruxolitinib was very active as a rescue therapy for patients with acute or chronic GVHD refractory to standard treatment. BioMed Central 2017-12-02 /pmc/articles/PMC5712115/ /pubmed/29214116 http://dx.doi.org/10.1186/s40164-017-0092-3 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Sarmiento Maldonado, Mauricio
Ramírez Villanueva, Pablo
Bertín Cortes-Monroy, Pablo
Jara Arias, Veronica
Soto Donoso, Katherine
Uribe Gonzalez, Pablo
Ocqueteau Tachini, Mauricio
Perez-Simón, Jose Antonio
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
title Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
title_full Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
title_fullStr Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
title_full_unstemmed Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
title_short Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
title_sort compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712115/
https://www.ncbi.nlm.nih.gov/pubmed/29214116
http://dx.doi.org/10.1186/s40164-017-0092-3
work_keys_str_mv AT sarmientomaldonadomauricio compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT ramirezvillanuevapablo compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT bertincortesmonroypablo compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT jaraariasveronica compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT sotodonosokatherine compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT uribegonzalezpablo compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT ocqueteautachinimauricio compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis
AT perezsimonjoseantonio compassionateuseofruxolitinibinacuteandchronicgraftversushostdiseaserefractorybothtocorticosteroidsandextracorporealphotopheresis